Abstract: Compositions and methods for treatment of toxin poisoning are disclosed.

Abstract: Compositions and methods for treatment of toxin poisoning are disclosed.

Abstract: Disclosed are specific mutants of L3 and transgenic plants that produce them. The plants exhibit increased resistance to fungal toxins that target ribosomal L3 protein. Also disclosed are transgenic plants that co-produce L3 mutant and an RIP protein, and exhibit increased resistance to various fungal toxins and viruses, while reducing toxicity normally associated with production of the RIP. Uses of the L3 mutants in animals are further disclosed.

Abstract: Disclosed are recombinant plant cells, plant cell parts, plant parts and transgenic plants containing a DNA molecule comprising a sequence encoding a Pokeweed Antiviral Protein (PAP) II protein. PAP II proteins include full length, wild-type PAP II and substantially nontoxic mutants or analogs including fragments thereof truncated at the C-terminus and other PAP II proteins having an intact catalytic active site amino acid residue E172 but that also have at least one amino acid substitution or deletion, and possess anti-viral and/or anti-fungal activity. DNA molecules comprising sequences encoding the mutants or analogs, as well as the isolated and purified PAP II proteins per se, are also disclosed. Methods of identifying nontoxic PAP II mutants are further disclosed. Transgenic plants that produce a PAP II protein exhibit anti-viral and/or anti-fungal activity. Virtually all flowering plants are included. Seed derived from the transgenic plants are also provided.

Abstract: Disclosed are transgenic plants containing an exogenous nucleic acid encoding an L3 protein. The plant exhibits increased resistance to viruses and/or fungi that infect plants. The L3 proteins include wild-type proteins, spontaneously occurring mutants and non-naturally occurring L3 mutants. Also disclosed are methods of reducing the toxicity of single-chain ribosome inhibitory proteins in cells, e.g., yeast, plant and animal cells, by co-administering the L3 protein with the RIP. Further disclosed are non-naturally occurring L3 mutants that (a) substantially fail to bind single-chain RIPs that bind endogenous L3 proteins, (b) are unable to maintain M1 killer virus, (c) promote altered programmed ribosomal frameshift efficiency, (d) exhibit resistance to peptidyltransferase inhibitors, and combinations of any of (a)-(d).

Abstract: Disclosed are transgenic plants having edible portions that produce methional during processing. The plants contain increased methionine levels such that upon processing of the edible portion(s), methional levels are increased and lead to food products that possess improved flavor stability and/or quality. Plants of the Solanaceous family e.g., potato, tomato and eggplant, and other methional-producing plants including maize and soybean, are preferred plants. Several ways of genetically engineering plants to produce increased free Met levels are disclosed, with introduction of a non-native nucleic acid encoding cystathionine gamma synthase (CGS) and tissue-specific expression of an anti-sense S-adenosyl-methionine synthetase being preferred. Also disclosed are methods for selecting transformed plant cells using ethionine and CGS as the selection agent and marker gene respectively.